NDLI: Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

Please wait, while we are loading the content...

Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections.

Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.

Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.

Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.

Medicinal Product Regulation: Portugal×³s Framework.

Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.

Anti-infective Dosing in Special Populations.

More on Antimicrobial Resistance, Linezolid, and Treating Special Populations.

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.

Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.

A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers.

Principles of Anti-infective Dosing in Pregnancy.

Year: 2016 Volume: 38 Issue: 8

Year: 2016 Volume: 38 Issue: 7

Year: 2016 Volume: 38 Issue: 6

Year: 2016 Volume: 38 Issue: 5

Year: 2016 Volume: 38 Issue: 4

Year: 2016 Volume: 38 Issue: 3

Year: 2016 Volume: 38 Issue: 2

Year: 2016 Volume: 38 Issue: 1

Year: 2015 Volume: 37

Year: 2014 Volume: 36

Year: 2013 Volume: 35

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Bailey, Robert A. Schwab, Phil Xu, Yihua Pasquale, Margaret Renda, Andrew
Description	Author Affiliation: Bailey RA ( Janssen Scientific Affairs LLC, Raritan, New Jersey.); Schwab P ( Comprehensive Health Insights, Inc, Humana Pharmacy, Louisville, Kentucky. Electronic address: pschwab@humana.com.); Xu Y ( Comprehensive Health Insights, Inc, Humana Pharmacy, Louisville, Kentucky.); Pasquale M ( Comprehensive Health Insights, Inc, Humana Pharmacy, Louisville, Kentucky.); Renda A ( Humana Inc, Louisville, Kentucky.)
Abstract	PURPOSE: Although the efficacy of canagliflozin has been well established in clinical trials, research regarding its use and impact on outcomes in clinical practice has been limited by the availability of data on observations up to and beyond 6 months after the initial use of canagliflozin. The purpose of this study was to evaluate changes in glycemic control after the initiation of canagliflozin use in a managed care population. METHODS: A retrospective cohort analysis in adults with type 2 diabetes mellitus was conducted using medical and pharmacy claims data and laboratory results from the Humana Research Database. The differences between hemoglobin (Hb) A1c levels pre- and postindex were assessed. Changes from pre- to postindex in the percentages of patients achieving glycemic control (eg, HbA1c <7% or <8%) were evaluated. HbA1c levels were also observed during days 31 to 90, 91 to 180, 181 to 270, and 271 to 360 postindex relative to preindex to assess the durability of HbA1c change over time. Analyses were conducted in the full cohort and in 3 subgroups: (1) HbA1c ≥7% at baseline; (2) age ≥65 years; (3) and Medicare members age ≥65 years and HbA1c ≥7% at baseline. FINDINGS: Among the 1562 patients meeting the study criteria, the mean HbA1c values pre- and postindex were 8.6% and 7.9%, respectively (P < 0.0001); in the subgroup with HbA1c ≥7% at baseline, these values were 8.9% and 8.0%; in the subgroup aged ≥65 years, 8.5% and 7.9%; and in the subgroup aged ≥65 years with HbA1c ≥7% at baseline, 8.8% and 8.1% (all subgroups, P < 0.001). The percentages of patients meeting glycemic-control thresholds (HbA1c <7%, <8%) were significantly greater at postindex in the full study cohort and in all 3 subgroups (all, P < 0.001). Based on longitudinal HbA1c results in the postindex periods, HbA1c reduction appeared durable across 12 months. IMPLICATIONS: The findings from this study suggest that treatment with canagliflozin is associated with improved glycemic control, as evidenced by HbA1c reduction and glycemic goal attainment. Even though not all patients had valid HbA1c measurements available in each quarter during the follow-up period, the reductions in mean HbA1c appeared durable across the postindex intervals. The observations from this majority Medicare Advantage with Prescription Drug sample and, more specifically, in the subgroups limited to patients aged ≥65 years are particularly informative for payers and providers managing or caring for patients of this age with diabetes.
File Format	HTM / HTML
ISSN	01492918
Issue Number	9
Journal	Clinical Therapeutics
Volume Number	38
e-ISSN	1879114X
Language	English
Publisher	Elsevier
Publisher Date	2016-09-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.

Medicare Managed Care: Observations about Medicare Cost Plans

The association between glycemic control and clinical outcomes after kidney transplantation.

Perceptions, Barriers, and Knowledge of Inpatient Glycemic Control: A Survey of Health Care Workers.

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.

Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population

National MTM Advisory Board comments on stakeholder proceedings on community pharmacy and managed care partnerships in quality.

Canagliflozin-Associated Acute Pancreatitis.

Nosocomial Infections and Outcomes after Intracerebral Hemorrhage: A Population-Based Study.

Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

Similar Documents

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.

Medicare Managed Care: Observations about Medicare Cost Plans

The association between glycemic control and clinical outcomes after kidney transplantation.

Perceptions, Barriers, and Knowledge of Inpatient Glycemic Control: A Survey of Health Care Workers.

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.

Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population

National MTM Advisory Board comments on stakeholder proceedings on community pharmacy and managed care partnerships in quality.

Canagliflozin-Associated Acute Pancreatitis.

Nosocomial Infections and Outcomes after Intracerebral Hemorrhage: A Population-Based Study.

Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.